For a long time, when people talked about biotechnology in the Asia-Pacific region, the conversation usually revolved around manufacturing.
The region became known for producing medicines, vaccines, active pharmaceutical ingredients (APIs), and other healthcare products for the global market. But today, that story is evolving.
According to Towards Healthcare Research and Consulting, the APAC biotechnology market was valued at US$ 372.23 billion in 2024, increased to US$ 432.72 billion in 2025, and is projected to reach US$ 1,611.67 billion by 2034, growing at a CAGR of 14.80%.
What stands out today is that manufacturing is no longer the region’s only strength. Countries across APAC are investing in research, supporting biotechnology startups, and creating an environment where new medicines and technologies can be developed.
Governments are increasing funding for life sciences, pharmaceutical companies are expanding research facilities, and startups are working on therapies that could improve the treatment of complex diseases.
China Is Writing a New Chapter
China has become one of the region’s most influential biotechnology markets.
The country continues to invest in biologics, antibody-drug conjugates (ADCs), gene therapies, AI-supported drug research, and advanced pharmaceutical manufacturing.
The biggest change is that many Chinese biotech companies are no longer focused only on supplying their domestic market.
Today, they are developing innovative medicines, partnering with global pharmaceutical companies, and becoming active contributors to international drug development.
Its combination of research investment, manufacturing expertise, and a large patient population is helping China strengthen its position in global biotechnology.
India Is Expanding Its Role
India has long been recognized for affordable medicines and vaccine production.
Now, it is building on that foundation by increasing investments in biosimilars, biologics, contract research, and biotechnology manufacturing.
Government programs, biotechnology parks, and research initiatives are encouraging companies to develop technologies within the country.
India’s experienced scientific workforce, cost-effective development environment, and strong pharmaceutical base give it a solid platform for future growth.
Japan Is Backing Long-Term Research
Japan’s priorities are shaped by its ageing population and growing healthcare needs.
This has led to continued investment in regenerative medicine, stem cell research, precision medicine, and advanced biologics.
Another advantage is the close collaboration between universities, research institutes, biotechnology companies, and pharmaceutical firms.
These partnerships support the long process of turning scientific discoveries into approved treatments.
South Korea Is Building More Than Manufacturing Capacity
South Korea has earned global recognition for biopharmaceutical manufacturing and CDMO services.
Today, the country is also expanding its work in biosimilars, cell therapies, and next-generation biologics.
Supported by strong government policies and advanced production facilities, South Korea is creating a biotechnology ecosystem that brings together research, development, manufacturing, and global partnerships.
Singapore Is Showing the Value of Quality Over Size
Singapore may be smaller than many of its regional neighbours, but it has built a strong biotechnology sector through research, infrastructure, and international collaboration.
The country attracts pharmaceutical and biotechnology companies looking for a regional base for research and high-value manufacturing.
Its universities and research institutes continue to support scientific progress and commercial innovation.
Australia Connects Research With Real-World Healthcare
Australia has established itself as an important centre for biomedical research, particularly in oncology, rare diseases, and advanced therapies.
Its strong clinical trial network also makes it an attractive destination for companies developing new treatments.
This combination helps move scientific discoveries from the laboratory to patients more efficiently.
Where the Next Wave of Growth May Come From
The biotechnology industry across APAC continues to open new opportunities.
Drug discovery is becoming faster, synthetic biology is creating new possibilities, mRNA research is expanding into more diseases, and cell and gene therapies are moving closer to everyday clinical practice.
Precision medicine is also becoming an important part of healthcare.
Instead of treating every patient in the same way, healthcare providers are increasingly developing treatments based on individual genetics and disease characteristics.
With a large population, improving healthcare systems, and growing research capabilities, APAC is well placed to contribute to this progress.
International pharmaceutical companies are also strengthening partnerships with biotechnology firms across the region, combining local scientific expertise with global development and commercialization experience.
A Region the World Is Watching
One of the biggest changes is how the global healthcare industry now views APAC.
The region is no longer known only for manufacturing medicines at scale.
It is increasingly recognised for discovering new treatments, conducting clinical research, developing biotechnology, and producing advanced therapies.
Each country brings its own strengths.
China offers scale and growing research capability.
India combines manufacturing expertise with scientific talent.
Japan continues to lead in regenerative and precision medicine.
South Korea has become a trusted partner in advanced biomanufacturing.
Singapore provides an internationally connected research environment.
Australia contributes high-quality biomedical research and clinical trial expertise.
Together, these strengths are creating a biotechnology ecosystem that is becoming more connected every year.
If research investment, scientific collaboration, talent development, and regulatory cooperation continue to grow, I believe APAC will play an even larger role in the future of global healthcare.
